Research ArticleCancer

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

See allHide authors and affiliations

Science Translational Medicine  01 Apr 2020:
Vol. 12, Issue 537, eaaz3577
DOI: 10.1126/scitranslmed.aaz3577

New ideas about neoantigens

Tumors with a low mutational burden are thought to have fewer neoantigens available for T cells to respond to and thus are not necessarily considered for checkpoint blockade therapy. Subudhi et al. treated patients with metastatic castration-resistant prostate cancer, which has a relatively low mutation burden, with ipilimumab. Patients who responded to the treatment had a T cell response signature and detectable neoantigen immunity. These results indicate that checkpoint blockade therapy with ipilimumab can instigate T cell responses to tumor neoantigens despite the tumor mutational burden status.

View Full Text

Stay Connected to Science Translational Medicine